Dr. Carabasi

Matthew Carabasi, MD

Contact Dr. Carabasi

925 Chestnut Street
Suite 320A
Philadelphia, PA 19107

(215) 955-8874

Most Recent Peer-reviewed Publications

  1. Sirolimus enhances remission induction in patients with high risk acute myeloid leukemia and mTORC1 target inhibition
  2. Higher rates of relapse in maternal recipients of haploidentical hematopoietic stem cell transplantation from adult offspring donors for AML and myelodysplastic syndrome
  3. Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States
  4. Improved survival after acute graft-versus-host disease diagnosis in the modern era
  5. Acquired uniparental disomy in chromosome 6p as a feature of relapse after T-cell replete haploidentical hematopoietic stem cell transplantation using cyclophosphamide tolerization
  6. A Two-Step Haploidentical Versus a Two-Step Matched Related Allogeneic Myeloablative Peripheral Blood Stem Cell Transplantation
  7. A two-step approach to myeloablative haploidentical transplantation: Low nonrelapse mortality and high survival confirmed in patients with earlier stage disease
  8. Clostridium difficile colonization and disease in patients undergoing hematopoietic stem cell transplantation
  9. No increased mortality from donor or recipient hepatitis B- and/or hepatitis C-positive serostatus after related-donor allogeneic hematopoietic cell transplantation
  10. Allogeneic Hematopoietic Cell Transplantation for Advanced Polycythemia Vera and Essential Thrombocythemia
  11. A2-step approach to myeloablative haploidentical stem cell transplantation: A phase 1/2 trial performed with optimized T-cell dosing
  12. Reducing the risk for transplantation-related mortality after allogeneic hematopoietic cell transplantation: How much progress has been made?
  13. Adenovirus DNA polymerase is recognized by human CD8+T cells
  14. Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia
  15. A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+hematologic malignancies
  16. Marrow ablative chemotherapy with hematopoietic stem cell rescue
  17. Improved Outcomes in Intermediate- and High-Risk Aggressive Non-Hodgkin Lymphoma after Autologous Hematopoietic Stem Cell Transplantation Substituting Intravenous for Oral Busulfan in a Busulfan, Cyclophosphamide, and Etoposide Preparative Regimen
  18. Comparison of graft-versus-host-disease and survival after HLA-identical sibling bone marrow transplantation in ethnic populations
  19. Severity of chronic graft-versus-host disease: Association with treatment-related mortality and relapse
  20. Fatal sickle cell crisis after granulocyte colony-stimulating factor administration [1]